PBLS Parabilis Medicines, Inc.
Price Chart
Executive Summary
Parabilis Medicines completed its IPO and simultaneously closed a $75M private placement with Regeneron at a 10% discount to the IPO price, issuing 4,166,666 shares. The company also adopted a classified board, supermajority vote requirements for director removal and bylaw amendments, and exclusive forum provisions. The Regeneron investment provides a strong strategic endorsement and capital, but the governance changes entrench the board and limit shareholder rights.
Key Financial Metrics
Actionable Insight
The Regeneron investment is a strong strategic signal that may support the stock near-term, but the governance entrenchment provisions are a clear negative for activist and governance-focused investors. Monitor for any early lock-up waiver or Regeneron stake disclosures. The next catalyst is likely pipeline data readouts or partnership announcements.
Key Facts
- Regeneron purchased $75M of PBLS common stock at 90% of the $20.00 IPO price, or $18.00 per share.
- The private placement closed concurrently with the IPO on June 11, 2026.
- 4,166,666 shares were issued to Regeneron in the private placement.
- The company adopted a classified board with three-year staggered terms for directors.
- Directors may only be removed for cause by a 2/3 supermajority vote.
- Stockholder action by written consent is eliminated (except for preferred stock).
- Special meetings may only be called by the board, not by stockholders.
- Bylaw amendments by stockholders require a 2/3 supermajority unless the board recommends the change.
- The charter authorizes 800M shares of common stock (600M voting, 200M non-voting) and 10M shares of undesignated preferred stock.
- Exclusive forum provisions designate Delaware Chancery Court for internal corporate claims and federal district courts for Securities Act claims.
Financial Impact
$75M capital infusion at a 10% discount to the IPO price, representing a ~4.2% stake based on the 100M shares outstanding post-IPO (assuming the IPO was 16.7M shares at $20 for ~$333M gross proceeds).
Risk Factors
- Governance entrenchment may deter activist investors and could lead to a governance discount in the stock.
- Regeneron's 4.99% beneficial ownership limitation on conversion of non-voting stock could limit liquidity and voting power alignment.
- The 10% discount to IPO price for Regeneron represents immediate dilution to public IPO investors.
- Classified board and supermajority requirements make it difficult for shareholders to effect change.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-267550 |
| Document: ck0001657677-ex10_1.htm | 0001193125-26-267550 |
| Document: ck0001657677-20260609.htm | 0001193125-26-267550 |
| Document: ck0001657677-ex3_1.htm | 0001193125-26-267550 |
| Document: 0001193125-26-267550-index-headers.html | 0001193125-26-267550 |
| Document: 0001193125-26-267550-index.html | 0001193125-26-267550 |
| Document: 0001193125-26-267550.txt | 0001193125-26-267550 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 16, 2026
4d ago
|
Insider Cluster
| $26.03 $25.85 | ▼ −0.69% | ▼ −1.47% | $25.85 (−0.69%) |
|
Jun 15, 2026
5d ago
|
Insider Cluster
| $26.59 $26.03 | ▼ −2.11% | ▼ −0.86% | $25.85 (−2.78%) |
|
Jun 11, 2026
9d ago
|
8-K
| $27.26 $25.01 | ▼ −8.25% | ▼ −10.02% | $25.85 (−5.17%) |
|
Jun 10, 2026
10d ago
|
424B4
| $30.31 $27.26 | ▼ −10.06% | ▼ −10.60% | $25.85 (−14.71%) |
|
Jun 10, 2026
11d ago
|
EFFECT
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
|
Jun 10, 2026
11d ago
|
3
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
|
Jun 10, 2026
11d ago
|
3
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
|
Jun 10, 2026
11d ago
|
3
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
|
Jun 10, 2026
11d ago
|
3
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
|
Jun 10, 2026
11d ago
|
3
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access